BOSTON SCIENTIFIC CORP — Director's Dealing 2018

Mar 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2018-03-14

Reporting Person: Ballinger Kevin J. (EVP & Pres, Interven Cardio)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-14	Common Stock	M	9375.0000	$6.2800	Acquired	113954.0000	Direct
2018-03-14	Common Stock	S	9375.0000	$28.3718	Disposed	104579.0000	Direct
2018-03-14	Common Stock	S	33428.0000	$28.3097	Disposed	71151.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-14	Stock Option (Right to Buy)	$6.2800	M	9375.0000	Disposed	2022-02-27	Common Stock (9375.0000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.27 to $28.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.17 to $28.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.